Approval Year
| Substance Class |
Concept
|
| Record UNII |
33VWC847G8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C20401
Created by
admin on Wed Apr 02 01:47:22 GMT 2025 , Edited by admin on Wed Apr 02 01:47:22 GMT 2025
|
||
|
FDA ORPHAN DRUG |
271208
Created by
admin on Wed Apr 02 01:47:22 GMT 2025 , Edited by admin on Wed Apr 02 01:47:22 GMT 2025
|
||
|
NCI_THESAURUS |
C129822
Created by
admin on Wed Apr 02 01:47:22 GMT 2025 , Edited by admin on Wed Apr 02 01:47:22 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C74005
Created by
admin on Wed Apr 02 01:47:22 GMT 2025 , Edited by admin on Wed Apr 02 01:47:22 GMT 2025
|
PRIMARY | NCIT | ||
|
33VWC847G8
Created by
admin on Wed Apr 02 01:47:22 GMT 2025 , Edited by admin on Wed Apr 02 01:47:22 GMT 2025
|
PRIMARY |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->LIGAND |
Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
This is a non-substance concept